HemoShear Gets $4.3M SBIR Grant to Develop Predictive Drug Technologies | GenomeWeb

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Biotech firm HemoShear today announced a $4.3 million Phase II Small Business Innovation Research grant to profile the effects of 50 known drugs on the human blood vessel system using the company's proprietary human vascular surrogate system.

The grant, the third received by the Charlottesville, Va.-based company in the past two years, is from the National Heart, Lung, and Blood Institute.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: a global genetic interaction map for Saccharomyces cerevisiae, and progress made in genomics, precision medicine, and therapeutics.

The price of plane tickets can affect how scientists in different countries choose to collaborate with each other, NPR reports.

The Annals of Improbable Research has awarded the 2016 Ig Nobel Prizes.

Scientific American alleges that the FDA has been "arm-twisting journalists into relinquishing their reportorial independence."